REGN
Regeneron Pharmaceuticals, Inc. · Healthcare · Biotechnology
TECHSellZACKSHold
R500#286 today
$735.20
+0.05% today · -6.71% 1W
Oct 2 close or latest
PreviewWhy it's moving
Moving with the market
- REGN +0.05% on the last session vs SPY +0.74%: −0.7 pts of stock-specific move.
- Aftermath, big drop (Sep 28): After its 60 big drops in the past 5 years, REGN typically gained 1.4% over the next month (median) and was higher 58% of the time; half the outcomes fell between -4.6% and +5.9%. An ordinary month: +1.1%. Among S&P 500 stocks after big drops, that ranks #275 of 500.
- Market backdrop (Fri): Average Hourly Earnings m/m 0.1% vs 0.3% expected (cooler); Non-Farm Employment Change 29K vs 89K expected (weaker); S&P futures +0.41%, 10-year yield -5bp in the 30 minutes after.
Assembled from Wallsti's own signals.
Next report
Oct 30
Before the open · in 26 days
EPS estimate
$15.99
$14.53 to $17.68 · 21 analysts
Revenue estimate
$4.5B
$4.3B to $4.8B
Track record
7/8 beats
last 8 reports · moved ±6.0% on average
Reports
| Reported | Quarter | EPS est. | EPS | EPS surprise | Revenue | Reaction | Gap | 5 days |
|---|---|---|---|---|---|---|---|---|
| Jul 30, 2026 BMO | 2Q2026 | $10.21 | $14.29 | +$4.08 (+40.0%) beat | $4.3B | +6.2% +4.5 vs SPY | +0.9% | +10.5% |
| Apr 29, 2026 BMO | 1Q2026 | $8.90 | $9.47 | +$0.57 (+6.4%) beat | $3.6B | -6.2% -6.2 vs SPY | -3.6% | -4.0% |
| Jan 30, 2026 BMO | 4Q2025 | $10.75 | $11.44 | +$0.69 (+6.4%) beat | $3.9B | -1.1% -0.8 vs SPY | +0.6% | +2.3% |
| Oct 28, 2025 BMO | 3Q2025 | $9.64 | $11.83 | +$2.19 (+22.7%) beat | $3.8B | +11.8% +11.6 vs SPY | +4.6% | +9.7% |
| Aug 1, 2025 BMO | $8.44 | $12.89 | +$4.45 (+52.7%) beat | — | +2.5% +4.1 vs SPY | +6.9% | +2.6% | |
| Apr 29, 2025 BMO | $8.48 | $8.22 | −$0.26 (−3.1%) miss | — | -6.9% -7.5 vs SPY | -8.0% | -1.2% | |
| Feb 4, 2025 BMO | $11.19 | $12.07 | +$0.88 (+7.9%) beat | — | +4.5% +3.9 vs SPY | -2.5% | +3.5% | |
| Oct 31, 2024 BMO | $11.70 | $12.46 | +$0.76 (+6.5%) beat | — | -9.2% -7.2 vs SPY | -5.2% | -11.5% | |
| Aug 1, 2024 BMO | $10.62 | $11.56 | +$0.94 (+8.9%) beat | — | +1.3% +2.7 vs SPY | -1.7% | -1.1% | |
| May 2, 2024 BMO | $10.10 | $9.55 | −$0.55 (−5.4%) miss | — | +3.8% +2.8 vs SPY | -0.4% | +5.8% | |
| Feb 2, 2024 BMO | $10.75 | $11.86 | +$1.11 (+10.3%) beat | — | -1.3% -2.4 vs SPY | +1.4% | -1.2% | |
| Nov 2, 2023 BMO | $10.78 | $11.59 | +$0.81 (+7.5%) beat | — | +3.5% +1.6 vs SPY | +0.1% | +4.0% | |
| Aug 3, 2023 BMO | $9.90 | $10.24 | +$0.34 (+3.4%) beat | — | +5.4% +5.7 vs SPY | +4.1% | +7.3% | |
| May 4, 2023 BMO | $9.56 | $10.09 | +$0.53 (+5.5%) beat | — | -6.1% -5.4 vs SPY | -3.4% | -6.7% | |
| Feb 3, 2023 BMO | $10.01 | $12.56 | +$2.55 (+25.5%) beat | — | +4.2% +5.3 vs SPY | +1.8% | -0.9% | |
| Nov 3, 2022 BMO | $9.48 | $11.14 | +$1.66 (+17.5%) beat | — | -0.2% +0.8 vs SPY | -1.9% | +0.3% | |
| Aug 3, 2022 BMO | $8.76 | $9.77 | +$1.01 (+11.5%) beat | — | +5.9% +4.3 vs SPY | +4.4% | +8.2% | |
| May 4, 2022 BMO | $9.80 | $11.49 | +$1.69 (+17.2%) beat | — | +0.1% -3.0 vs SPY | +0.1% | -6.9% | |
| Feb 4, 2022 BMO | $20.30 | $23.72 | +$3.42 (+16.8%) beat | — | +0.4% -0.1 vs SPY | -1.7% | -0.4% | |
| Nov 4, 2021 BMO | $9.94 | $15.37 | +$5.43 (+54.6%) beat | — | -0.7% -1.2 vs SPY | +0.8% | -4.6% | |
| Aug 5, 2021 BMO | $17.71 | $25.80 | +$8.09 (+45.7%) beat | — | — | — | — | |
| May 6, 2021 BMO | $8.68 | $9.89 | +$1.21 (+13.9%) beat | — | — | — | — | |
| Feb 5, 2021 BMO | $8.29 | $9.53 | +$1.24 (+15.0%) beat | — | — | — | — | |
| Nov 5, 2020 BMO | $6.99 | $8.36 | +$1.37 (+19.6%) beat | — | — | — | — |
BMO = before the open, AMC = after the close. Reaction: the first session that could trade on the report (the same day for BMO, the next session for AMC) against the close before it; "vs SPY" subtracts the S&P 500 over the same session. EPS surprise is in dollars, with the percentage only when the estimate is at least $0.10 (near zero, a small beat would show as hundreds of percent). Revenue surprise needs the estimate from before the report, so it starts with the reports Wallsti saw coming.
Analyst estimates
| Period | EPS | Range | vs year ago | 90-day trend | Revisions 30d | Revenue | vs year ago |
|---|---|---|---|---|---|---|---|
| Current quarter · Sep 30, 2026 | $15.99 (21) | $14.53 – $17.68 | +35% | +22.3% | ▲0 ▼1 | $4.5B | +21% |
| Next quarter · Dec 31, 2026 | $15.97 (21) | $10.47 – $23.62 | +40% | +22.2% | ▲1 ▼0 | $4.7B | +21% |
| Current year · Dec 31, 2026 | $54.77 (27) | $43.42 – $62.71 | +24% | +18.5% | ▲3 ▼1 | $17.0B | +19% |
| Next year · Dec 31, 2027 | $50.63 (9) | $42.52 – $57.25 | +15% | +5.2% | ▲5 ▼3 | $18.5B | +9% |
Consensus as of Oct 4, 2026. Source: Yahoo Finance analyst estimates; schedule and timing also from Nasdaq's earnings calendar.